Advancing new potential treatments for certain GI diseases affecting millions of patients in need
  • Compound
  • Indication
  • Approval
  • linaclotide Partner
  • IBS-C/FC in pediatrics

Status of selected key development programs as of December 1, 2020. Represents ongoing phase of development; does not correspond to completion of a particular phase.

Partnering Opportunities

As a GI focused, US healthcare company, we are interested in discussing opportunities to collaborate on GI products. We are also seeking partners in territories outside of the US for select current development programs. Please contact us with more details on your area of interest.

Partner with Us

Copyright © 2021, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.